Ocular Therapeutix, Inc. provided revenue guidance for the full year 2022. For the year, the company expected total net product revenue to be in the range of $55 million to $60 million, representing growth of between 26% to 38% over 2021. The growth is anticipated to be primarily driven by sales of DEXTENZA for the treatment of post-surgical inflammation and pain.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.29 USD | +1.94% | +11.52% | +41.03% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+41.03% | 956M | |
+34.35% | 693B | |
+29.39% | 584B | |
-3.49% | 372B | |
+20.15% | 332B | |
+6.19% | 294B | |
+14.11% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+9.21% | 168B |
- Stock Market
- Equities
- OCUL Stock
- News Ocular Therapeutix, Inc.
- Ocular Therapeutix, Inc. Provides Revenue Guidance for the Full Year 2022